Coherus Oncology (CHRS) Cash & Current Investments (2012 - 2026)

Coherus Oncology has disclosed Cash & Current Investments across 15 years of filings, most recently posting $167.0 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $167.0 million, up 102.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $167.0 million (up 102.7% YoY), and the FY2025 annual result was $172.1 million, up 36.62% from the prior year.
• Cash & Current Investments came in at $167.0 million for Q1 2026 at Coherus Oncology, down from $172.1 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $325.7 million in Q1 2022 to a low of $82.4 million in Q1 2025.
• The 5-year median for Cash & Current Investments is $167.0 million (2026), against an average of $182.1 million.
• Across the five-year window, Cash & Current Investments soared 102.81% in 2024 and tumbled 68.28% in 2025, its largest moves.
• Coherus Oncology's Cash & Current Investments stood at $191.7 million in 2022, then slumped by 38.57% to $117.7 million in 2023, then gained by 7.0% to $126.0 million in 2024, then surged by 36.62% to $172.1 million in 2025, then retreated by 2.95% to $167.0 million in 2026.
• The last three Cash & Current Investments figures came in at $167.0 million (Q1 2026), $172.1 million (Q4 2025), and $191.7 million (Q3 2025), per Business Quant data.